424 related articles for article (PubMed ID: 18195134)
1. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
[TBL] [Abstract][Full Text] [Related]
2. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.
Sriram U; Barcellos LF; Villoslada P; Rio J; Baranzini SE; Caillier S; Stillman A; Hauser SL; Montalban X; Oksenberg JR
Genes Immun; 2003 Mar; 4(2):147-52. PubMed ID: 12618863
[TBL] [Abstract][Full Text] [Related]
5. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
Vandenbroeck K; Matute C
Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
[TBL] [Abstract][Full Text] [Related]
7. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.
Alvarez-Lafuente R; Blanco-Kelly F; Garcia-Montojo M; Martínez A; De Las Heras V; Dominguez-Mozo MI; Bartolome M; Garcia-Martinez A; De la Concha EG; Urcelay E; Arroyo R
Mult Scler; 2011 May; 17(5):513-20. PubMed ID: 21177319
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K
Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B
Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966
[TBL] [Abstract][Full Text] [Related]
11. Interferon inhibitory activity in patients with multiple sclerosis.
Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy.
Pappas DJ; Oksenberg JR
Neurology; 2010 Jan; 74 Suppl 1():S62-9. PubMed ID: 20038765
[TBL] [Abstract][Full Text] [Related]
13. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.
O'Doherty C; Villoslada P; Vandenbroeck K
Cytokine Growth Factor Rev; 2007; 18(3-4):211-22. PubMed ID: 17540610
[TBL] [Abstract][Full Text] [Related]
15. Measures in the first year of therapy predict the response to interferon beta in MS.
Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
[TBL] [Abstract][Full Text] [Related]
16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
18. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
[TBL] [Abstract][Full Text] [Related]
19. Identification of disease causing loci using an array-based genotyping approach on pooled DNA.
Craig DW; Huentelman MJ; Hu-Lince D; Zismann VL; Kruer MC; Lee AM; Puffenberger EG; Pearson JM; Stephan DA
BMC Genomics; 2005 Sep; 6():138. PubMed ID: 16197552
[TBL] [Abstract][Full Text] [Related]
20. HLA class II and response to interferon-beta in multiple sclerosis.
Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E
Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
